target icon View trials by
therapeutic target
phase icon View trials
by phase
cancer type icon View trials by
cancer type

Advanced Solid Tumors

Enrolling
Neuroblastoma or Pediatric Cancer
Abemaciclib
Enrolling
Colorectal Cancer, NSCLC, or Other Advanced Solid Tumors
LY3537982
Enrolling
Lung Cancer, Medullary Thyroid Cancer, or Other Advanced Solid Tumors
LOXO-260
Enrolling
Advanced Solid Tumors
LOXO-435
Enrolling
NSCLC, Medullary Thyroid Cancer, Papillary Thyroid Carcinoma, or Other Advanced Solid Tumors
Selpercatinib
Enrolling
Pediatric Cancer
Selpercatinib

Breast Cancer

Breast Cancer
Abemaciclib
Breast Cancer or NSCLC
Abemaciclib
Breast Cancer
Abemaciclib
Breast Cancer or Endometrial Cancer
Imlunestrant
Enrolling
Enrolling
Enrolling
Advanced Solid Tumors
LOXO-783

Gastrointestinal Cancer

Enrolling
Colorectal Cancer, NSCLC, or Other Advanced Solid Tumors
LY3537982

Genitourinary Cancer

Prostate Cancer
Abemaciclib
Prostate Cancer
Abemaciclib
Enrolling
Prostate Cancer
Abemaciclib

Gynecologic Cancer

Breast Cancer or Endometrial Cancer
Imlunestrant

Hematologic Cancer

CLL/SLL or NHL
Pirtobrutinib
Enrolling
Enrolling
Enrolling
Enrolling
Enrolling

Lung Cancer

Breast Cancer or NSCLC
Abemaciclib
Enrolling
Colorectal Cancer, NSCLC, or Other Advanced Solid Tumors
LY3537982
Enrolling
Lung Cancer, Medullary Thyroid Cancer, or Other Advanced Solid Tumors
LOXO-260
Enrolling
Lung Cancer or NSCLC
LY3537982

Sarcoma

Enrolling

Thyroid Cancer

Enrolling
Lung Cancer, Medullary Thyroid Cancer, or Other Advanced Solid Tumors
LOXO-260
Medullary Thyroid Cancer
Selpercatinib

The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.